Martin F Haslanger

Apex Therapeutics, Inc.

$195,182

Attributed

$465,386

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $240.3K · FY2009–13

$250K$187.5K$125K$62.5K$0

'09

'10

'11

'12

'13

Funding mix

By agency

NIH$465,386 · 2

By mechanism

R43$240,322 · 1

R41$225,064 · 1

Top collaborators

Mark R. Kelley2 shared
Xiaoxi Qiao1 shared

Most similar at Apex Therapeutics, Inc.

Same institution · by research overlap

Xiaoxi Qiao$75,021

Others in their field

Top investigators on “Age Related Macular Degeneration”

Keri Hammel · The Emmes Company, Llc$53,700,408
Rohit Varma · University Of Southern California$50,124,787
Maureen G Maguire · University Of Pennsylvania$38,506,792
Cecilia Sungmin Lee · University Of Washington$32,086,169
Krzysztof Palczewski · University Of California-Irvine$27,513,979
Supriya Menezes · The Emmes Company, Llc$25,277,032

Research focus

Age Related Macular DegenerationAlternative TherapiesAmericanAnalogAngiogenesisAngiogenesis InhibitorsAnimal ModelAnimalsAntiangiogenesis TherapyAreaAutomobile DrivingAvastinBaseBevacizumabBlindnessCell GrowthCell ProliferationCellsChoroidal NeovascularizationClinical ManagementCombined Modality TherapyDiabetic RetinopathyDna Repair EnzymesAcrylic Acid

Grant awards (2)

Novel Therapeutic Strategy for Refractory and Relapse Childhood Acute Leukemia$240,322

R43 · FY2013 · CA · contact PI

Redox protein APE1/Ref-1 as a target for age-related macular degeneration (AMD)$225,064

R41 · FY2009 · EY · contact PI